Skip to main content

Desmopressin

Desmopressin (DDAVP) is a synthetic vasopressin V2-receptor agonist with three established urologic uses: (1) nocturia from nocturnal polyuria in adults — its principal indication; (2) primary monosymptomatic nocturnal enuresis in children; and (3) perioperative hemostasis in patients with mild hemophilia A or von Willebrand disease Type I undergoing urologic surgery. It is the only antidiuretic agent specifically indicated for nocturia due to nocturnal polyuria, but use is gated by the risk of hyponatremia — a class effect with formulation-specific boxed warnings. An older-formulation observational cohort reported a 13-fold higher rate than oxybutynin; this is not a risk estimate for the current low-dose sublingual regimen.[1][2][3][4]

For the broader nocturia evaluation framework, see Nocturia. For the storage-OAB pharmacology landing, see Storage / OAB.

Pharmacology​

Mechanism​

Desmopressin is a modified vasopressin analogue (deaminated cysteine-1, D-arginine-8) that yields:[5]

  • Selective V2 agonism in the renal collecting duct → aquaporin-2 trafficking to the apical membrane → free-water reabsorption → reduced urine production
  • Markedly decreased V1 (vascular) activity — clinically antidiuretic doses are below the vasopressor threshold
  • Hemostatic effect — increases circulating von Willebrand factor (vWF) and factor VIII activity; response varies and must be established for the bleeding disorder
  • Prolonged duration vs native AVP — antidiuretic half-life ~2–3 h; hemostatic effect 8–12 h

Pharmacokinetics by formulation​

FormulationOnsetNotes
Oral tabletAntidiuretic onset ~1 h; peak 4–7 hBioavailability 0.08–0.16%
Orally disintegrating tablet (ODT, Nocdurna)Sublingual absorptionNot affected by nasal congestion or GI transit; no fluid intake required[7]
Intranasal sprayPeak ~1.5 hProlonged half-life → higher hyponatremia risk; intranasal is no longer approved for enuresis[8]
IV / SC injectionMinutesHemostasis and central DI; the CDI injection dose is approximately 1/10th the intranasal maintenance dose, with individual reassessment[5]

Formulations — doses are not interchangeable​

FormulationBrandsDose rangePrimary urologic indication
Oral tabletGeneric, DDAVP0.1–0.6 mgCDI, primary nocturnal enuresis, off-label nocturia
Sublingual tablet (NOCDURNA)27.7 / 55.3 µg desmopressin acetateWomen 27.7 µg; men 55.3 µg, 1 h before bedAdults with NP and ≥2 nocturnal voids; equivalent to 25 / 50 µg desmopressin free base[3]
Low-dose intranasal (NOCTIVA; historical US label)0.83 / 1.66 µg desmopressin acetate per sprayAge/risk-based, not sex-based; ≥65 yr or increased hyponatremia risk starts at 0.83 µgAdults with NP and ≥2 nocturnal voids; verify current availability and product instructions[23]
Standard intranasal (DDAVP NS)10–40 µgCDI; not approved for enuresis
IV / SCDDAVP Injection0.3 µg/kg IV (max 20 µg) for hemostasis; CDI uses a separate regimen belowHemophilia A, vWD Type I, CDI[5][6]

Urologic Applications​

1. Nocturia from nocturnal polyuria (adults)​

The dominant urologic use. Nocturnal polyuria — defined as nocturnal urine production exceeding 20–33% of 24-hour output (age-dependent) — can arise from several causes, including altered nocturnal AVP secretion, sleep apnea and fluid redistribution. Desmopressin reduces urine production but does not replace evaluation or treatment of the underlying cause.[1]

Efficacy.

  • A Cochrane review of 14 RCTs (2,966 men) found desmopressin reduces nocturnal voids by 0.46–0.85 per night vs placebo, with the larger effect at 3–12 months (MD −0.85, 95% CI −1.17 to −0.53).[9]
  • A systematic review of 10 RCTs (2,191 patients) found a 100 µg dose provided ~1 additional hour of undisturbed sleep before the first void and 0.72 fewer voids per night vs placebo.[10]
  • Effect size is larger in patients with documented NP and at higher oral doses.[4][9]
  • Desmopressin has a similar effect on nocturnal voids as alpha-blockers (MD 0.30, 95% CI −0.20 to 0.80; moderate quality), and adding desmopressin to an alpha-blocker yields only a small, likely unimportant additional reduction.[9]
  • Real-world data in older men (60–95 yr) starting at 0.1 mg oral showed reductions of 2–3 voids/night, 660–705 mL in nocturnal urine volume, and 1–2 h more undisturbed sleep; 70.1% completed 3 months and 16.7% discontinued for hyponatremia detected on monitoring.[11]

Sex-specific dosing (FDA-approved Nocdurna ODT):

PatientDose
Women27.7 µg desmopressin acetate (=25 µg desmopressin), SL 1 h before bed
Men55.3 µg desmopressin acetate (=50 µg desmopressin), SL 1 h before bed

Women have higher serum desmopressin concentrations and greater hyponatremia risk at equivalent doses — the rationale for sex-stratified dosing.[2][3]

Older adults. The AGS Beers Criteria (2023) recommends avoiding desmopressin for nocturia / NP in older adults due to hyponatremia risk, favoring behavioral interventions (the "SCREeN" approach: Sleep, Cardiovascular, Renal, Endocrine, Neurological) and alternative pharmacotherapy (β3-agonists, alpha-blockers) instead.[12] An observational oral-tablet regimen does not establish a routine geriatric prescribing standard. If treatment is selected after individualized risk assessment, use the specific product label and early sodium surveillance; oral and sublingual microgram doses cannot be substituted.[3][6]

2. Primary monosymptomatic nocturnal enuresis (children ≥ 6 yr)​

Desmopressin is one of the two first-line treatments (the other being enuresis alarms).[8][13]

Updated efficacy — Cochrane 2025. Across 98 studies (8,699 participants), desmopressin reduced wet nights versus placebo by about 1.81 per week (95% CI 1.39–2.24 fewer; low certainty) and increased achievement of 14 consecutive dry nights during treatment (RR 3.18, 95% CI 1.75–5.80; moderate certainty). End-of-treatment results may resemble alarm therapy, but alarms give more durable dryness after treatment. Adding an alarm to desmopressin reduced wet nights by 0.88 per week versus desmopressin alone (moderate certainty). These pooled findings do not establish permanent cure after medication stops.[24]

Dosing is formulation- and jurisdiction-specific. The US DDAVP oral tablet label for children ≥6 years starts at 0.2 mg at bedtime and permits titration to 0.6 mg. UK enuresis DesmoMelt starts at 120 µg and permits 240 µg; its label begins at age 5. These enuresis melts are not the US NOCDURNA nocturia product and are not interchangeable tablet-for-tablet or microgram-for-microgram.[3][6][25]

Practical points.[7][8]

  • Take 1 hour before the last void before bed
  • Restrict fluids from 1 h before to 8 h after dosing
  • Effective only on the night of administration — daily use for continuous effect; can be used as-needed for sleepovers / camp
  • Reassess response, timing, fluid intake and dose before declaring failure; NICE assesses response at 4 weeks. Continue an effective course for 3 months, then reassess the need for treatment with a drug holiday.[26]
  • Intranasal is no longer approved for enuresis due to high hyponatremia risk
  • The most common cause of unresponsiveness is reduced nocturnal bladder capacity, not polyuria

The International Consultation on Incontinence assigns desmopressin a Level 1, Grade A recommendation in monosymptomatic enuresis.[7]

3. Neurogenic LUTD nocturia and frequency​

Small studies describe off-label treatment of selected neurological patients with documented nocturnal polyuria; this is not a routine treatment for neurogenic frequency:[14][15]

  • Multiple sclerosis — most studied population; symptom relief for 6 h[14][15]
  • Parkinson's disease — useful for autonomic-dysfunction-related NP[14]
  • Spinal cord injury — patients lose normal diurnal AVP variation, producing NP; desmopressin reduces nocturnal output (small studies)[15][16]
  • Other: multiple system atrophy, stroke, neural tube defects[15]

A meta-analysis of 14 studies (200 patients, mostly MS) found significantly fewer nocturnal voids (MD −0.75, 95% CI −1.10 to −0.41).[15]

Selection: distinguish excess urine production from impaired bladder storage and assess fluid balance, renal function and sodium. NOCDURNA is contraindicated in heart failure and eGFR <50 mL/min/1.73 m²; neurologic disease does not override these restrictions.[3]

4. Perioperative hemostasis in urologic surgery​

FDA-approved for hemostasis in mild hemophilia A (factor VIII > 5%) and mild-to-moderate vWD Type I (factor VIII > 5%) during surgery. Establish responsiveness and coordinate with hematology.[5]

Dose. 0.3 µg/kg IV (max 20 µg) over 15–30 min, given 30 min before the procedure; repeat dosing, if needed, depends on the clinical and laboratory response and sodium/fluid monitoring.[5]

Tachyphylaxis. May occur with administration more often than every 48 h; the response is reproducible if given every 2–3 days.[5]

Urologic relevance.

  • Useful for known mild bleeding disorders undergoing TURP, prostatectomy, cystoscopy with biopsy, or other urologic procedures in patients with demonstrated responsiveness[5][17]
  • ASA Practice Guidelines for Perioperative Blood Management note placebo-controlled meta-analytic evidence that desmopressin reduces postoperative blood loss (Category A1-B)[17]
  • US injection labeling is limited to the specified mild hemophilia A and Type I vWD populations; it is ineffective for severe classic hemophilia or factor VIII antibodies. Type 2B vWD carries thrombocytopenia/thrombosis risk; other vWD subtypes require hematology-directed treatment.[5]
  • Not standard for routine post-TURP hematuria in patients without bleeding disorders — manage bleeding according to its severity and source; any antifibrinolytic use requires a procedure-specific assessment[18]

5. Central diabetes insipidus​

Urologists may encounter transient central DI after transsphenoidal pituitary surgery or head trauma — massive polyuria with polydipsia.[6][19][20]

RouteDose
OralStart 0.05 mg BID; range 0.1–1.2 mg/day in divided doses
IV / SC2–4 µg/day in 1–2 doses
Intranasal10–40 µg/day

Adjust to urine volume and osmolality; titrate morning and evening doses separately to preserve diurnal rhythm. Ineffective for nephrogenic DI.[6]

Hyponatremia — the dose-limiting safety concern​

The defining toxicity. NOCDURNA and the cited injection label carry an FDA boxed warning; wording and contraindications must be checked by formulation rather than assumed identical across all products.[3][5]

Epidemiology​

  • A population-based cohort study reported a hyponatremia rate of 146 per 1,000 person-years with desmopressin vs 11 per 1,000 with oxybutynin — a 13-fold higher rate (HR 13.19; 95% CI 6.69–26.01); at 30 days the rate was 19-fold higher (HR 19.41).[21]
  • In the real-world older-male cohort, 16.7% discontinued for hyponatremia detected on routine monitoring.[11]
  • Hyponatremia (RR 5.1) and headache (RR 4.3) are the most common adverse events in meta-analysis.[10]

Risk factors[21][22]​

  • Age ≥ 65 years — the dominant risk factor
  • Extremes of age (pediatric and geriatric)
  • Intranasal formulations (longer half-life)
  • Concurrent diuretic use (especially loop diuretics)
  • Systemic or inhaled glucocorticoids
  • Polydipsia / excessive fluid intake
  • CHF, CKD, SIADH, cystic fibrosis
  • Intercurrent illness with fluid shifts (GI illness)

Contraindications — NOCDURNA label[3]​

  • Hyponatremia or history of hyponatremia
  • Excessive fluid intake / polydipsia
  • Loop diuretics or systemic / inhaled glucocorticoids
  • Known or suspected SIADH
  • Conditions that cause fluid or electrolyte imbalance
  • Renal impairment with eGFR <50 mL/min/1.73 m²
  • Heart failure or uncontrolled hypertension

Required monitoring for nocturia formulations[3][23]​

  1. Confirm normal serum sodium before starting or resuming
  2. Recheck within 7 days of initiation or resumption; repeat after dose escalation when applicable
  3. Recheck at ~ 1 month
  4. Periodic monitoring thereafter
  5. More frequent monitoring in patients ≥ 65 or with risk factors
  6. Hold or stop if hyponatremia occurs

Patient counseling — symptoms of water intoxication[6]​

Headache, nausea / vomiting, weight gain, fatigue, lethargy, disorientation, muscle weakness or cramps, irritability, decreased appetite, restlessness. Severe: seizure, coma, respiratory arrest. Discontinue and call if these develop.

Fluid restriction[6][7]​

Keep fluid intake to a minimum from 1 h before through 8 h after dosing; this window also applies to the cited DDAVP tablet label for enuresis. Suspend enuresis treatment during acute vomiting, diarrhea, fever or other circumstances requiring increased fluid intake.

Other Adverse Effects​

  • Headache (RR 4.3 vs placebo)[10]
  • Slight BP elevation (rare with oral; more common with intranasal / IV at high doses)
  • Facial flushing (with IV)
  • Nausea, abdominal cramps
  • Rare serious hypersensitivity, including anaphylaxis; review the specific product label
  • Theoretical thrombotic risk from factor VIII elevation

Drug Interactions[22]​

  • Loop diuretics, thiazides — increase hyponatremia risk (loop diuretics are a contraindication for nocturia formulations)
  • SSRIs, SNRIs, TCAs — may potentiate hyponatremia via SIADH
  • NSAIDs — may potentiate antidiuretic effect
  • Carbamazepine, chlorpromazine — may enhance antidiuretic effect
  • Glucocorticoids (systemic / inhaled) — contraindicated with nocturia formulations

Practical Prescribing Summary​

IndicationFormulationDoseMonitoring
Nocturia (NP) — womenNOCDURNA SL27.7 µg acetate (=25 µg desmopressin), 1 h before bedNa⁺ at baseline, within 7 d, 1 mo, then periodic
Nocturia (NP) — menNOCDURNA SL55.3 µg acetate (=50 µg desmopressin), 1 h before bedSame
Nocturia — older adultsIndividualized; Beers recommends avoidanceDo not adopt an observational oral-tablet regimen as the defaultIf used, apply early label-based sodium checks, with closer monitoring for age/risk
Nocturnal enuresis (US ≥6 yr)US oral tablet; regional enuresis melts have separate labelingUS tablet 0.2 mg → 0.6 mg qhs; UK DesmoMelt 120 → 240 µg (≥5 yr)Na⁺ if symptoms; mandatory fluid restriction
Neurogenic nocturiaSelected off-label useSpecialist assessment of confirmed NP and product-specific regimenApply renal/fluid contraindications and sodium monitoring; not a general treatment for frequency
Perioperative hemostasisIV0.3 µg/kg (max 20 µg) over 15–30 min, 30 min pre-opFactor VIII, Na⁺; tachyphylaxis if < 48 h interval
Central DIOral / IN / IV-SCStart PO 0.05 mg BID; total 0.1–1.2 mg/day in divided doses; IV-SC 2–4 µg/day; IN 10–40 µg/dayUrine volume, osmolality, Na⁺

Clinical Positioning​

  • Document nocturnal polyuria with a bladder diary (≥ 33% of 24-h output overnight, or age-adjusted threshold) before starting — not every "nocturia" patient has NP, and patients without NP need cause-directed treatment (for example, storage treatment for OAB, outlet treatment for BPH, or treatment of a sleep disorder)
  • First-line behavioral measures — fluid restriction in the evening, leg elevation, compression stockings for dependent edema, address apnea and CHF
  • Add desmopressin when behavioral measures are inadequate and NP is confirmed
  • Older adults — Beers Criteria recommend avoidance; if used, start lowest dose with rigorous sodium monitoring
  • Sodium monitoring is essential — baseline plus 7-day plus 1-month plus periodic sodium monitoring is the standard; this is not a set-and-forget medication

See Also​

References​

1. Weiss JP, Everaert K. "Management of nocturia and nocturnal polyuria." Urology. 2019;133S:24–33. doi:10.1016/j.urology.2019.09.022

2. Chung E. "Desmopressin and nocturnal voiding dysfunction: clinical evidence and safety profile in the treatment of nocturia." Expert Opin Pharmacother. 2018;19(3):291–298. doi:10.1080/14656566.2018.1429406

3. NOCDURNA (desmopressin acetate) sublingual tablets: US prescribing information. DailyMed label updated October 19, 2023. Official label. Accessed September 11, 2026.

4. Han J, Jung JH, Bakker CJ, Ebell MH, Dahm P. "Desmopressin for treating nocturia in men." Cochrane Database Syst Rev. 2017;10:CD012059. doi:10.1002/14651858.CD012059.pub2

5. Desmopressin acetate injection: US prescribing information. DailyMed, 2025 label. Official label.

6. DDAVP (desmopressin acetate) tablets: US prescribing information. DailyMed label updated February 3, 2021. Official label.

7. Vande Walle J, Rittig S, Bauer S, et al. "Practical consensus guidelines for the management of enuresis." Eur J Pediatr. 2012;171(6):971–983. doi:10.1007/s00431-012-1687-7

8. Robson WL. "Evaluation and management of enuresis." N Engl J Med. 2009;360(14):1429–1436. doi:10.1056/NEJMcp0808009

9. Han J, Jung JH, Bakker CJ, Ebell MH, Dahm P. "Desmopressin for treating nocturia in men." BJU Int. 2018;122(4):549–559. doi:10.1111/bju.14183

10. Ebell MH, Radke T, Gardner J. "A systematic review of the efficacy and safety of desmopressin for nocturia in adults." J Urol. 2014;192(3):829–835. doi:10.1016/j.juro.2014.03.095

11. Chu C, Lin CC. "Real-world safety and effectiveness of an initial 0.1 mg dose of desmopressin in older men with nocturnal polyuria." J Urol. 2026. doi:10.1097/JU.0000000000005003

12. Steinman MA. "Alternative treatments to selected medications in the 2023 American Geriatrics Society Beers Criteria®." J Am Geriatr Soc. 2025;73(9):2657–2677. doi:10.1111/jgs.19500

13. Lauters RA, Garcia KW, Arnold JJ. "Enuresis in children: common questions and answers." Am Fam Physician. 2022;106(5):549–556.

14. Panicker JN, Fowler CJ, Kessler TM. "Lower urinary tract dysfunction in the neurological patient: clinical assessment and management." Lancet Neurol. 2015;14(7):720–732. doi:10.1016/S1474-4422(15)00070-8

15. Hajebrahimi S, Darvishi A, HajEbrahimi R, et al. "Efficacy and safety of desmopressin in nocturia and nocturnal polyuria control of neurological patients: a systematic review and meta-analysis." Neurourol Urodyn. 2024;43(1):167–182. doi:10.1002/nau.25291

16. Kilinç S, Akman MN, Levendoglu F, Ozker R. "Diurnal variation of antidiuretic hormone and urinary output in spinal cord injury." Spinal Cord. 1999;37(5):332–335. doi:10.1038/sj.sc.3100814

17. American Society of Anesthesiologists Task Force on Perioperative Blood Management. "Practice guidelines for perioperative blood management." Anesthesiology. 2015;122(2):241–275. doi:10.1097/ALN.0000000000000463

18. Te AE, Te AG, Ramaswamy A, Kaplan SA. "Practical management of hematuria after endoscopic surgery for benign prostatic obstruction." Prostate Cancer Prostatic Dis. 2026. doi:10.1038/s41391-026-01111-w

19. Angelousi A, Alexandraki KI, Mytareli C, Grossman AB, Kaltsas G. "New developments and concepts in the diagnosis and management of diabetes insipidus (AVP-deficiency and resistance)." J Neuroendocrinol. 2023;35(1):e13233. doi:10.1111/jne.13233

20. Tomkins M, Lawless S, Martin-Grace J, Sherlock M, Thompson CJ. "Diagnosis and management of central diabetes insipidus in adults." J Clin Endocrinol Metab. 2022;107(10):2701–2715. doi:10.1210/clinem/dgac381

21. Fralick M, Schneeweiss S, Wallis CJD, Jung EH, Kesselheim AS. "Desmopressin and the risk of hyponatremia: a population-based cohort study." PLoS Med. 2019;16(10):e1002930. doi:10.1371/journal.pmed.1002930

22. Chin X, Teo SW, Lim ST, et al. "Desmopressin therapy in children and adults: pharmacological considerations and clinical implications." Eur J Clin Pharmacol. 2022;78(6):907–917. doi:10.1007/s00228-022-03297-z

23. US Food and Drug Administration. NOCTIVA (desmopressin acetate) nasal spray: prescribing information. 2017 approval label, sections 2–5. FDA label. Historical formulation information; this citation does not establish current commercial availability.

24. Hahn D, Stewart F, Raman G. Desmopressin for nocturnal enuresis in children. Cochrane Database Syst Rev. 2025;7:CD002112. doi:10.1002/14651858.CD002112.pub2. Review summary.

25. Ferring Pharmaceuticals. DesmoMelt 120/240 micrograms oral lyophilisate: UK Summary of Product Characteristics. SmPC. Accessed September 12, 2026.

26. NICE. Bedwetting in under 19s (CG111): recommendations, desmopressin treatment. Guideline. Accessed September 12, 2026.